INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
491.4 EUR
+5.3 (+1.09%)
We assign a fundamental rating of 6 out of 10 to IUI1. IUI1 was compared to 65 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IUI1 a very profitable company, without any liquidiy or solvency issues. IUI1 is valued quite expensive, but it does show an excellent growth. These ratings would make IUI1 suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
IUI1 had positive earnings in the past year.
IUI1 had a positive operating cash flow in the past year.
Each year in the past 5 years IUI1 has been profitable.
In the past 5 years IUI1 always reported a positive cash flow from operatings.
1.2 Ratios
IUI1 has a better Return On Assets (14.19%) than 92.31% of its industry peers.
Looking at the Return On Equity, with a value of 16.12%, IUI1 is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 11.69%, IUI1 belongs to the best of the industry, outperforming 83.08% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 9.72%.
The last Return On Invested Capital (11.69%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
The Profit Margin of IUI1 (28.58%) is better than 98.46% of its industry peers.
IUI1's Profit Margin has declined in the last couple of years.
IUI1 has a Operating Margin of 29.44%. This is amongst the best in the industry. IUI1 outperforms 98.46% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
IUI1 has a better Gross Margin (66.38%) than 70.77% of its industry peers.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
Compared to 5 years ago, IUI1 has more shares outstanding
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.34
WACC8.75%
2.3 Liquidity
IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.97, IUI1 belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
IUI1 has a Quick Ratio of 4.20. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IUI1 (4.20) is better than 95.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.47% yearly.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y19.93%
EPS Next 2Y16.17%
EPS Next 3Y15.85%
EPS Next 5Y15.47%
Revenue Next Year21.17%
Revenue Next 2Y18.1%
Revenue Next 3Y16.53%
Revenue Next 5Y14.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 66.59 indicates a quite expensive valuation of IUI1.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 63.08% of the companies listed in the same industry.
IUI1 is valuated expensively when we compare the Price/Earnings ratio to 26.46, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 57.95, which means the current valuation is very expensive for IUI1.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 72.31% of the companies are valued more cheaply.
IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.59 | ||
| Fwd PE | 57.95 |
4.2 Price Multiples
69.23% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IUI1 is valued a bit more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 89.47 | ||
| EV/EBITDA | 55.9 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has a very decent profitability rating, which may justify a higher PE ratio.
IUI1's earnings are expected to grow with 15.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.34
PEG (5Y)5.8
EPS Next 2Y16.17%
EPS Next 3Y15.85%
5. Dividend
5.1 Amount
IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IUI1 (12/5/2025, 7:00:00 PM)
491.4
+5.3 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.66%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap174.20B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts78.54
Price Target533.91 (8.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)4.2%
PT rev (3m)3.61%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)3.25%
EPS NY rev (1m)5.67%
EPS NY rev (3m)5.61%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)1.24%
Revenue NY rev (3m)1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.59 | ||
| Fwd PE | 57.95 | ||
| P/S | 21.14 | ||
| P/FCF | 89.47 | ||
| P/OCF | 68.64 | ||
| P/B | 11.92 | ||
| P/tB | 12.17 | ||
| EV/EBITDA | 55.9 |
EPS(TTM)7.38
EY1.5%
EPS(NY)8.48
Fwd EY1.73%
FCF(TTM)5.49
FCFY1.12%
OCF(TTM)7.16
OCFY1.46%
SpS23.24
BVpS41.21
TBVpS40.37
PEG (NY)3.34
PEG (5Y)5.8
Graham Number82.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC8.75%
ROIC/WACC1.34
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y19.93%
EPS Next 2Y16.17%
EPS Next 3Y15.85%
EPS Next 5Y15.47%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.17%
Revenue Next 2Y18.1%
Revenue Next 3Y16.53%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.66%
EBIT Next 5Y20.46%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
What is the valuation status of INTUITIVE SURGICAL INC (IUI1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Price/Earnings (PE) ratio for INTUITIVE SURGICAL INC (IUI1.DE) is 66.59 and the Price/Book (PB) ratio is 11.92.
What is the earnings growth outlook for INTUITIVE SURGICAL INC?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 19.93% in the next year.